Biophytis

Biophytis is a  clinical-stage biotech company specialized in developing therapeutics to slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from Covid-19.

Its lead product candidate, Sarconeos (BIO101), is a small molecule, administered orally and targeted to treat mobility disability in elderly patients with sarcopenia. It is in early clinical stages in the US and Europe. It is also being studied for the treatment of severe respiratory manifestations of Covid-19 in Europe, Brazil, and the US. 

As of November 2023, a pediatric formulation, BIO101, is being developed with an Investigational New Drug application granted for the treatment of Duchenne Muscular Dystrophy. The company was granted FDA IND approval for this formulation in December 2019.

The other drug candidate, Macuneos (BIO201), is an orally administered small molecule in development targeted for retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease.

Biophytis has been listed on the Euronext Growth Paris market since July 2015.

Key customers and partnerships

In September 2023, Biophytis partnered with Skyepharma, a French pharmaceutical company, for the production of regulatory batches of BIO101 in severe forms of Covid-19. Based on the active ingredient produced by SEQENS, Skyepharma was to develop finished product batches meeting the Good Manufacturing Practice (GMP) standards required for market access filings. The key stages in the production of BIO101 was to be carried out by leading French partners. Pharmaceutical development work at the industrial stage was to complete the information required for early access authorizations, particularly in France and Brazil.

Funding and financials 

The company reported nil revenue in 2022 and 2021. The net loss for 2022 was USD 24,216 while the net loss in the preceding year amounted to USD 31,164.